Sandesh Mahatme Sells 50,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sandesh Mahatme sold 50,000 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Sarepta Therapeutics, Inc. (SRPT) traded down 0.46% on Friday, reaching $36.70. 1,272,093 shares of the company were exchanged. Sarepta Therapeutics, Inc. has a 12-month low of $24.96 and a 12-month high of $63.73. The firm’s market capitalization is $2.36 billion. The stock’s 50-day moving average is $37.38 and its 200 day moving average is $33.02.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the previous year, the firm posted ($1.19) EPS. The firm’s revenue for the quarter was up 350000.0% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/sandesh-mahatme-sells-50000-shares-of-sarepta-therapeutics-inc-nasdaqsrpt-stock-updated-updated-updated.html.

Several equities analysts have recently weighed in on the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $102.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, April 23rd. Vetr lowered shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $37.67 price target on the stock. in a research report on Monday, April 24th. Royal Bank Of Canada lowered their price target on shares of Sarepta Therapeutics from $91.00 to $60.00 and set an “outperform” rating on the stock in a research report on Friday, April 28th. Credit Suisse Group reaffirmed an “outperform” rating and set a $64.00 price target on shares of Sarepta Therapeutics in a research report on Friday, April 28th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, April 28th. Eight investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus price target of $61.28.

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Asymmetry Capital Management L.P. raised its position in shares of Sarepta Therapeutics by 82.2% in the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock valued at $5,353,000 after buying an additional 71,630 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 271 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Sarepta Therapeutics by 85.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock valued at $704,000 after buying an additional 9,635 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Sarepta Therapeutics by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 1,435 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $3,806,000. 63.11% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply